Abstract 412P
Background
HCC is one of the most prevalent cancers with high death rate in Asia. To understand tumoral heterogeneity, differences between tumor and adjacent liver tissue at molecular level and tumor microenvironment (TME) change after multi-targeted kinase inhibitor sorafenib (Sora) treatment (Tx), DSP was used for protein profiling in pre- and post- Sora Tx HCC formalin-fixed, paraffin-embedded (FFPE) samples.
Methods
Total 25 FFPE slides from 13 HCC patients were analyzed by GeoMxTM DSP protein next generation sequencing, including 9 patients with paired pre- and post- Sora Tx HCC samples. Using EGFR and MET immunohistochemistry (IHC) expression level as references, total 332 regions of interest (ROIs) were identified from tumor tissue and adjacent non-tumor liver tissue for DSP protein profiling. Besides Human Protein Core, 8 more panels were selected to cover key cancer signaling and immune-related proteins in the experiment. Multivariate linear regression was used to investigate the difference at different tissue type, Tx status and individual level.
Results
EGFR abundance measured by DSP was significantly higher in EGFR IHC-high (IHC score = 3+) compared with IHC-low (IHC score ≤ 1+) group (p = 4.96e-15). Similar trend observed in MET expression between DSP and IHC further warranted the performance of DSP protein profiling. Hierarchical clustering revealed expression patterns of ROIs from different cells of origin. Known IO targets such as PD-1 (p = 1.17e-10) was with higher abundance in ROIs of liver tumor region comparing to those of adjacent hepatocytes. When focusing on liver tumor region, most markers such as Phospho-AKT1 and Phospho-ERK1/2 upregulated in post- Sora ROIs which reflects the cell proliferation signal at disease progression after Sora Tx. IO targets under clinical development such as GITR and Tim-3 also showed upregulation in post-Tx ROIs.
Conclusions
This study, to our knowledge, represents the first DSP analysis of HCC and shows high concordance with IHC results. Immune and molecular pattern discovered in different tissue type and Tx stage improved our understanding of HCC TME and provided insights for future HCC clinical development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
C.J. Yen: Non-Financial Interests, Personal, Principal Investigator: National Cheng Kung University college of medicine. M. Qing, Q. Wu, X. Lyu, M. Xia, F. Yang, H. Xu: Financial Interests, Personal, Full or part-time Employment: Janssen research& development. L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Janssen Research & Development.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract